Dendreon ends antigen supply deal with GSK
This article was originally published in Scrip
Executive Summary
Dendreon revealed in a Securities and Exchange Commission filing that it is ending its development and supply agreement for antigen used in its prostate cancer immunotherapy Provenge (sipuleucel-T) with GlaxoSmithKline, effective 31 October.